Alexis A. Thompson

12.9k citations

213 papers · 5.1k indexed · 1 hit paper · h-index 41

Genetics top 0.1%
Hematology top 0.2%
Pediatrics, Perinatology and Child Health top 1%
Molecular Biology top 10%
Genetics top 2%

Co-authors: Robert I. Liem Sherif M. Badawy Janet L. Kwiatkowski Patricia J. Giardina Ellis J. Neufeld Elliott Vichinsky John C. Wood Stella T. Chou
Topics: Hemoglobinopathies and Related Disorders (153 papers)Iron Metabolism and Disorders (63 papers)Prenatal Screening and Diagnostics (38 papers)
Cited by: Genetics Hematology Pediatrics, Perinatology and Child Health
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences The Lancet
Partner nations: United States United Kingdom France

In The Last Decade

Alexis A. Thompson

203 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B

2003 578 citations Alexis A. Thompson et al. Blood profile →

Peers

Countries citing papers authored by Alexis A. Thompson

Since Specialization

Citations

This map shows the geographic impact of Alexis A. Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexis A. Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexis A. Thompson more than expected).

Fields of papers citing papers by Alexis A. Thompson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexis A. Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexis A. Thompson. The network helps show where Alexis A. Thompson may publish in the future.

Co-authorship network of co-authors of Alexis A. Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of Alexis A. Thompson. A scholar is included among the top collaborators of Alexis A. Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexis A. Thompson. Alexis A. Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Successful Engraftment, Increased Hemoglobin, and Reduced Transfusion Dependence in Patients with Transfusion-Dependent Beta-Thalassemia Treated in the Edithal Trial 2025 ·Transplantation and Cellular Therapy ·Haydar Frangoul,(unknown),(unknown),Kai‐Hsin Chang,Michael Jaskolka,Keunpyo Kim,Baisong Mei,Olubunmi Afonja,Alexis A. Thompson	0
2	Post-Approval, Real-World Experience with Betibeglogene Autotemcel for Transfusion-Dependent Beta Thalassemia 2025 ·Transplantation and Cellular Therapy ·(unknown),David F. Friedman,Caitlin W. Elgarten,(unknown),Eugene Khandros,(unknown),(unknown),Lisa Wray,Yongping Wang,Alexis A. Thompson,Janet L. Kwiatkowski,Timothy S. Olson	0
3	Betibeglogene Autotemcel (Beti-cel) Gene Addition Therapy Results in Durable Hemoglobin A (HbA) Production with up to 10 Years of Follow-up in Participants with Transfusion-Dependent β-Thalassemia 2025 ·Transplantation and Cellular Therapy ·Timothy S. Olson,Alexis A. Thompson,Janet L. Kwiatkowski,Jennifer Schneiderman,Isabelle Thuret,Andreas E. Kulozik,Evangelia Yannaki,Marina Cavazzana,Suradej Hongeng,Martin G. Sauer,Adrian J. Thrasher,Ashutosh Lal,John E.J. Rasko,(unknown),Tao Ge,(unknown),(unknown),Mark C. Walters,Franco Locatelli	0
4	Postpartum and Lactation-Related Genitourinary Symptoms 2025 ·Obstetrics and Gynecology ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Caroline Andy,(unknown),Thomas Drew,(unknown),(unknown),Aditi Shah,(unknown),(unknown),Alexis A. Thompson,Jill M. Krapf,Rachel Rubin	1
5	The Impact of Designing Near-Peer Teacher Training According to Merrill’s First Principles of Instruction 2024 ·Medical Science Educator ·(unknown),(unknown),Alexis A. Thompson,Hannah R. Morris,Lauren Cıfuentes	0
6	American Society of Hematology: building a comprehensive minority recruitment and retention professional program 2024 ·Blood Advances ·(unknown),Rahma Warsame,Melody Smith,Arturo Molina,Rayne H. Rouce,Belinda R. Avalos,Cage S. Johnson,José A. López,Alexis A. Thompson,(unknown),(unknown),(unknown),(unknown),(unknown),Christopher R. Flowers,Deirdra R. Terrell	1
7	Real‐world evidence: Long‐term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years 2024 ·American Journal of Hematology ·Janet L. Kwiatkowski,Alexis A. Thompson,Fernando Tricta,(unknown),(unknown),Caroline Fradette,Sherif M. Badawy	0
8	Safety and Efficacy Outcomes in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT) Receiving Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-thalassemia) Gene Therapy in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies 2021 ·Transplantation and Cellular Therapy ·Mark C. Walters,Janet L. Kwiatkowski,John B. Porter,Suradej Hongeng,Evangelia Yannaki,Andreas E. Kulozik,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,Ruiting Guo,Weijian Liu,Richard A. Colvin,Franco Locatelli,Alexis A. Thompson	1
9	Resolution of Serious Vaso-Occlusive Pain Crises: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy 2021 ·Transplantation and Cellular Therapy ·Mark C. Walters,Alexis A. Thompson,Markus Y. Mapara,Janet L. Kwiatkowski,Lakshmanan Krishnamurti,Banu Aygün,Kimberly A. Kasow,(unknown),Manfred Schmidt,(unknown),Francis J. Pierciey,(unknown),Ren Chen,Sunita Goyal,Julie Kanter,John F. Tisdale	1
10	Efficacy and Safety of Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-thalassemia) Gene Therapy in 60 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed for up to 6 Years Post-Infusion 2021 ·Transplantation and Cellular Therapy ·Suradej Hongeng,Alexis A. Thompson,Janet L. Kwiatkowski,Franco Locatelli,John B. Porter,John E.J. Rasko,Marina Cavazzana,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,Andreas E. Kulozik,Evangelia Yannaki,Manfred Schmidt,(unknown),Ruiting Guo,Weijian Liu,Richard A. Colvin,Mark C. Walters	1
11	A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy 2021 ·Blood Advances ·Sherif M. Badawy,(unknown),Robert I. Liem,Sonali Chaudhury,Alexis A. Thompson	42
12	Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia 2020 ·Blood ·Alexis A. Thompson,Janet L. Kwiatkowski,John B. Porter,Suradej Hongeng,Evangelia Yannaki,Andreas E. Kulozik,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,Ruiting Guo,Weijian Liu,Richard A. Colvin,Mark C. Walters,Franco Locatelli	7
13	Long-Term Efficacy and Safety of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia: Results in Patients with up to 6 Years of Follow-up 2020 ·Blood ·Janet L. Kwiatkowski,Mark C. Walters,Suradej Hongeng,Franco Locatelli,(unknown),Marina Cavazzana,Ying Chen,Richard A. Colvin,Alexis A. Thompson	8
14	Association between Participants’ Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease 2018 ·BioMed Research International ·Sherif M. Badawy,Leonardo Barrera,(unknown),Alexis A. Thompson	32
15	Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease 2018 ·Pediatric Hematology and Oncology ·Sherif M. Badawy,Alexis A. Thompson,Jane L. Holl,Frank J. Penedo,Robert I. Liem	43
16	Patient-Centered eHealth Interventions for Children, Adolescents, and Adults With Sickle Cell Disease: Systematic Review 2018 ·Journal of Medical Internet Research ·Sherif M. Badawy,Robert M. Cronin,Jane S. Hankins,Lori E. Crosby,Michael R. DeBaun,Alexis A. Thompson,Nirmish Shah	113
17	Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults 2017 ·Health and Quality of Life Outcomes ·Sherif M. Badawy,Alexis A. Thompson,(unknown),Frank J. Penedo,Karen Rychlik,Robert I. Liem	68
18	Barriers to hydroxyurea adherence and health‐related quality of life in adolescents and young adults with sickle cell disease 2017 ·European Journal Of Haematology ·Sherif M. Badawy,Alexis A. Thompson,Frank J. Penedo,Jin‐Shei Lai,Karen Rychlik,Robert I. Liem	64
19	Medication Adherence and Technology-Based Interventions for Adolescents With Chronic Health Conditions: A Few Key Considerations 2017 ·JMIR mhealth and uhealth ·Sherif M. Badawy,Alexis A. Thompson,Lisa M. Kuhns	66
20	Widespread B29 (CD79b) Gene Defects and Loss of Expression in Chronic Lymphocytic Leukemia 1999 ·Leukemia & lymphoma ·Alexis A. Thompson,(unknown),Andrew Saxon,Randolph Wall	16

About Alexis A. Thompson

Alexis A. Thompson is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health, having authored 213 papers that have together received 5.1k indexed citations. Recurring topics across this work include Hemoglobinopathies and Related Disorders (153 papers), Iron Metabolism and Disorders (63 papers) and Prenatal Screening and Diagnostics (38 papers). The work is most often cited by research in Genetics (3.1k citations), Hematology (2.7k citations) and Pediatrics, Perinatology and Child Health (980 citations). Alexis A. Thompson has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Robert I. Liem, Sherif M. Badawy, Janet L. Kwiatkowski, Patricia J. Giardina, Ellis J. Neufeld, Elliott Vichinsky, John C. Wood, Stella T. Chou, Thomas D. Coates and Frank J. Penedo. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact